BRD3 and cancer: JQ1 is a competitive inhibitor of acetylated lysine, binding to the bromodomains of BRD3 (Kd ∼59 nM), BRD4 (Kd ∼49 nM), and BRD2 (Kd ∼128 nM)42 that can disrupt functions of SEs in cancer, inflammation and atherogenesis through BRD4 inhibition23,42,43.